Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | CuttingEdgeInfo Reports | Monitoring and Ensuring Pharmaceutical Compliance (PH113)

Monitoring and Ensuring Pharmaceutical Compliance (PH113)

Compliance is at the forefront of pharma companies’ minds today. Companies face the threat of staggering fines and increased scrutiny from regulatory bodies. A growing level of public distrust of the industry also carries a negative effect on companies’ reputations. These events have created a new regulatory environment that has dramatically affected companies’ organizational structures and practices. In fact, the industry’s most influential companies have reexamined—and sometimes reinvented—the way they do business.

This new landscape thrusts compliance groups into the center of the action. Compliance teams have gained additional resources and a stronger tie to executive leadership. But with this increased power comes challenges in communicating regulatory changes, in training and testing employees, and in ensuring compliance across an organization.

This report examines the current state of compliance management at some of the pharmaceutical industry’s top companies. It looks at metrics and strategies surrounding three aspects of compliance success:

* Structure, Headcounts and Investment – Provides up-to-date structuring strategies, headcounts and investments of top compliance groups

* Monitoring and Ensuring Compliance – Details companies’ strategies regarding monitoring, training, testing, documentation, firewalls, and much more

* Activities and Challenges – Examines the focus and reach of top compliance functions. Also looks at the impact and reactions to some recent regulations. Finally, survey respondents rate the challenges facing compliance efforts moving forward.

Companies Included in Report

Allergan

Bayer

Biogen Idec

CV Therapeutics

Dyax

EMD Serono

GlaxoSmithKline

Janssen-Ortho

Johnson & Johnson

Pfizer

Novartis

Schering-Plough

Two large biotechnology companies

Upsher-Smith

….plus more

Published 2008

104 Pages

300+ Metrics

50+ Charts and Diagrams
Table of Contents
Price: $7,695.00 / €5,147.96

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions